

MedGenome is really excited to share the news of \$50 million investment led by Novo Holdings, an international investor in healthcare and life sciences and a part of Novo Nordisk Foundation. Existing investors LeapFrog Investments and Sofina have also participated in this round.

MedGenome is strongly poised to broaden its portfolio of genetic testing solutions, bioinformatics solutions, SaaS offerings and much more. We are keen to expand our reach and access to new markets in Africa and Middle East while strengthening our leadership position in India and South-East Asia market.

“MedGenome team has built a model of accessibility across South Asia that delivers cutting-edge diagnostic tests, at the same global standard of quality as other market leaders, and at a fraction of the cost,” said **Mahesh Pratapneni, Group CEO of MedGenome**.

He added, “We’re thrilled to have the support of Novo holdings, leader in international life sciences, investing behind us as we expand into new global markets and scale access to affordable and life-changing testing.”

“India’s healthcare ecosystem now understands the value of genomics. Today, concerted efforts are being made to incorporate insights derived from genome sequencing in the diagnosis and management of complex diseases. Our partnership with Novo Holdings will strengthen our core diagnostics tests development and research projects to support drug discovery across the world.” **Vedam Ramprasad, PhD, Chief Executive Officer (India) of MedGenome Labs**.

“MedGenome is committed to revolutionizing the healthcare space with path-breaking genomics solutions. We intend to elevate the scale and ambit of our diagnostic services and strive to communize genetic testing, leveraging its benefits for public health, worldwide. The partnership with Novo Holdings will help us expand our genetic test portfolio to serve the growing unmet need in emerging markets. The investment will further strengthen our existing research efforts and mark our foray into newer markets like Africa and the Middle East—mainstreaming personal healthcare and genetic testing.” **Surajit Chakrabarty, Chief Financial Officer, MedGenome Labs**

MedGenome has been a pioneer and leader in genetic testing, genomics solutions and drug discovery space having administered more than 300,000 complex genetic tests and served over 200,000 patients. We are dedicated to democratizing the power of genetics for consistently delivering personalized, proactive, and affordable diagnostic solutions and services to every patient in need.

MedGenome offers comprehensive genetic testing solutions under its specialized brands - Actia (Inherited disease genetics), Claria (Reproductive genetics), Micra (Infectious disease genetics), Prima (Cancer genetics) and Genessense (Genetic Wellness).

For full details on what we do and what drives us, please [click here](#)